Pulmonary Nodulosis and Aseptic Granulomatous Lung Disease Occurring in Patients with Rheumatoid Arthritis Receiving Tumor Necrosis Factor-α-Blocking Agent: A Case Series

REFERENCES

1. 1.↵
   1. Kaiser MJ,
   2. Bozonnat MC,
   3. Jorgensen C,
   4. Daurès JP,
   5. Sany J

   . Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis. Arthritis Rheum 2002;46:559–60.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Mackley CL,
   2. Ostrov BE,
   3. Ioffreda MD

   . Accelerated cutaneous nodulosis during infliximab therapy in a patient with rheumatoid arthritis. J Clin Rheumatol 2004;10:336–8.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Cunnane G,
   2. Warnock M,
   3. Fye KH,
   4. Daikh DI

   . Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002;47:445–9.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Ognenovski VM,
   2. Clark Ojo T,
   3. Fox DA

   . Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol 2008;35:2279–82.

   OpenUrlFREE Full Text
5. 5.↵
   1. Ziff M

   . The rheumatoid nodule. Arthritis Rheum 1990;33:761–7.

   OpenUrlPubMed
6. 6.↵
   1. Boros DL

   . Granulomatous inflammations. Prog Allergy 1978;24:183–267.

   OpenUrlPubMed
7. 7.↵
   1. Wikaningrum R,
   2. Highton J,
   3. Parker A,
   4. Coleman M,
   5. Hessian PA,
   6. Roberts-Thompson PJ,
   7. et al.

   Pathogenic mechanisms in the rheumatoid nodule: comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. Arthritis Rheum 1998;41:1783–97.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Scrivo R,
   2. Sparado A,
   3. Iagnocco A,
   4. Valesini G

   . Appearance of rheumatoid nodules following anti-tumor necrosis factor treatment with adalimumab for rheumatoid arthritis. Clin Exp Rheumatol 2007;25:117.

   OpenUrlPubMed
9. 9.↵
   1. Kekow J,
   2. Welte T,
   3. Kellner U,
   4. Pap T

   . Development of rheumatoid nodules during anti-tumor necrosis factor with etanercept. Arthritis Rheum 2002;46:843–4.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Hubscher O,
    2. Re R,
    3. Iotti R

    . Pulmonary rheumatoid nodules in an etanercept-treated patient. Arthritis Rheum 2003;48:2077–8.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Van Ede AE,
    2. Den Broeder AA,
    3. Wagenaar M,
    4. Van Riel PLCM,
    5. Creemers MCW

    . Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. J Rheumatol 2007;34:1590–2.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Watson P,
    2. Simler N,
    3. Sceaton N,
    4. Lillicrap M

    . Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis. Rheumatology 2008;47:928–9.

    OpenUrlFREE Full Text
13. 13.↵
    1. Peno-Green L,
    2. Lluberas G,
    3. Kingsley T,
    4. Brantley S

    . Lung injury linked to etanercept therapy. Chest 2002;122:1858–60.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Yousem SA,
    2. Dacic S

    . Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Modern Pathol 2005;18:651–5.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Kudrin A,
    2. Chilvers ER,
    3. Ginawi A,
    4. Hazleman BL,
    5. Griffiths MH,
    6. Thiru S,
    7. et al.

    Sarcoid-like granulomatous disease following etanercept treatment for rheumatoid arthritis. J Rheumatol 2007;34:648–50.

    OpenUrlFREE Full Text
16. 16.↵
    1. Calvert GM,
    2. Rice FL,
    3. Boiano JM,
    4. Sheehy JW,
    5. Sanderson WT

    . Occupational silica exposure and risk of various diseases: an analysis using death certificates from 27 states of the United States. Occup Environ Med 2003;60:122–9.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Furst DE,
    2. Wallis R,
    3. Broder M,
    4. Beenhouwer DO

    . Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159–67.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. De Bandt M,
    2. Saint-Marcoux B

    . Tumour necrosis factor alpha blockade and the risk of vasculitis. Ann Rheum Dis 2006;65:1534–5.

    OpenUrlFREE Full Text
19. 19.↵
    1. Ramos-Casals M,
    2. Brito-Zeron P,
    3. Soto MJ,
    4. Cuadrado MJ,
    5. Khamashta MA

    . Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847–61.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Toussirot E,
    2. Pertuiset E,
    3. Wendling D

    . Sarcoidosis occuring during anti-TNF treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008;26:471–5.

    OpenUrlPubMed
21. 21.↵
    1. Verrecchia F,
    2. Pessah M,
    3. Atfi A,
    4. Mauviel A

    . Tumor necrosis factor alpha inhibits transforming growth factor beta/Smad signaling in human dermal fibroblast via AP-1 activation. J Biol Chem 2000;275:30226–31.

    OpenUrlAbstract/FREE Full Text